Patents by Inventor Mark Eller

Mark Eller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190274980
    Abstract: One embodiment of the present invention is to improve the safety and efficacy of the administration of GHB or a salt thereof to a patient. It has been discovered that the concomitant administration of an MCT inhibitor, such as diclofenac, valproate, or ibuprofen, will affect GHB administration. For example, it has been discovered that diclofenac lowers the effect of GHB in the body, thereby potentially causing an unsafe condition. Furthermore, it has been discovered that valproate increases the effect of GHB on the body, thereby potentially causing an unsafe condition.
    Type: Application
    Filed: January 10, 2019
    Publication date: September 12, 2019
    Inventor: Mark Eller
  • Publication number: 20190200369
    Abstract: A facility for performing employing multiple frequencies in a secure distributed hierarchical convergence network is described. The facility receives a signal in a first frequency, converts the received signal to an internal representation, applies a business rule to the converted signal, and, when the business rule indicates that the signal should be transmitted in a second frequency, causes the internal representation of the signal to be translated to a second frequency and transmitted in the second frequency.
    Type: Application
    Filed: October 8, 2018
    Publication date: June 27, 2019
    Inventors: Mark L. Tucker, Jeremy Bruestle, Riley Eller, Brian Retford, Choong Ng
  • Patent number: 10213400
    Abstract: One embodiment of the present invention is to improve the safety and efficacy of the administration of GHB or a salt thereof to a patient. It has been discovered that the concomitant administration of an MCT inhibitor, such as diclofenac, valproate, or ibuprofen, will affect GHB administration. For example, it has been discovered that diclofenac lowers the effect of GHB in the body, thereby potentially causing an unsafe condition. Furthermore, it has been discovered that valproate increases the effect of GHB on the body, thereby potentially causing an unsafe condition.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: February 26, 2019
    Assignee: JAZZ PHARMACEUTICALS IRELAND LIMITED
    Inventor: Mark Eller
  • Publication number: 20180263936
    Abstract: Provided herein are pharmaceutical compositions and formulations comprising mixed salts of gamma-hydroxybutyrate (GHB). Also provided herein are methods of making the pharmaceutical compositions and formulations, and methods of their use for the treatment of sleep disorders such as apnea, sleep time disturbances, narcolepsy, cataplexy, sleep paralysis, hypnagogic hallucination, sleep arousal, insomnia, and nocturnal myoclonus.
    Type: Application
    Filed: September 19, 2017
    Publication date: September 20, 2018
    Inventors: Clark P. Allphin, Gunjan Junnarkar, Roman Skowronski, Cuiping Chen, Katayoun Zomorodi, Mark Eller, Philip McGarrigle
  • Publication number: 20180200210
    Abstract: One embodiment of the present invention is to improve the safety and efficacy of the administration of GHB or a salt thereof to a patient. It has been discovered that the concomitant administration of an MCT inhibitor, such as diclofenac, valproate, or ibuprofen, will affect GHB administration. For example, it has been discovered that diclofenac lowers the effect of GHB in the body, thereby potentially causing an unsafe condition. Furthermore, it has been discovered that valproate increases the effect of GHB on the body, thereby potentially causing an unsafe condition.
    Type: Application
    Filed: January 12, 2018
    Publication date: July 19, 2018
    Inventor: Mark Eller
  • Publication number: 20170049731
    Abstract: One embodiment of the present invention is to improve the safety and efficacy of the administration of GHB or a salt thereof to a patient. It has been discovered that the concomitant administration of an MCT inhibitor, such as diclofenac, valproate, or ibuprofen, will affect GHB administration. For example, it has been discovered that diclofenac lowers the effect of GHB in the body, thereby potentially causing an unsafe condition. Furthermore, it has been discovered that valproate increases the effect of GHB on the body, thereby potentially causing an unsafe condition.
    Type: Application
    Filed: November 4, 2016
    Publication date: February 23, 2017
    Inventor: Mark Eller
  • Patent number: 9486426
    Abstract: One embodiment of the present invention is to improve the safety and efficacy of the administration of GHB or a salt thereof to a patient. It has been discovered that the concomitant administration of an MCT inhibitor, such as diclofenac, valproate, or ibuprofen, will affect GHB administration. For example, it has been discovered that diclofenac lowers the effect of GHB in the body, thereby potentially causing an unsafe condition. Furthermore, it has been discovered that valproate increases the effect of GHB on the body, thereby potentially causing an unsafe condition.
    Type: Grant
    Filed: May 8, 2015
    Date of Patent: November 8, 2016
    Assignee: Jazz Pharmaceuticals Ireland Limited
    Inventor: Mark Eller
  • Publication number: 20160015662
    Abstract: One embodiment of the present invention is to improve the safety and efficacy of the administration of GHB or a salt thereof to a patient. It has been discovered that the concomitant administration of an MCT inhibitor, such as diclofenac, valproate, or ibuprofen, will affect GHB administration. For example, it has been discovered that diclofenac lowers the effect of GHB in the body, thereby potentially causing an unsafe condition. Furthermore, it has been discovered that valproate increases the effect of GHB on the body, thereby potentially causing an unsafe condition.
    Type: Application
    Filed: May 8, 2015
    Publication date: January 21, 2016
    Inventor: Mark Eller
  • Patent number: 9050302
    Abstract: One embodiment of the present invention is to improve the safety and efficacy of the administration of GHB or a salt thereof to a patient. It has been discovered that the concomitant administration of an MCT inhibitor, such as diclofenac, valproate, or ibuprofen, will affect GHB administration. For example, it has been discovered that diclofenac lowers the effect of GHB in the body, thereby potentially causing an unsafe condition. Furthermore, it has been discovered that valproate increases the effect of GHB on the body, thereby potentially causing an unsafe condition.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: June 9, 2015
    Assignee: Jazz Pharmaceuticals Ireland Limited
    Inventor: Mark Eller
  • Patent number: 8952029
    Abstract: One embodiment of the present invention is to improve the safety and efficacy of the administration of GHB or a salt thereof to a patient. It has been discovered that the concomitant administration of an MCT inhibitor, such as diclofenac, valproate, or ibuprofen, will affect GHB administration. For example, it has been discovered that diclofenac lowers the effect of GHB in the body, thereby potentially causing an unsafe condition. Furthermore, it has been discovered that valproate increases the effect of GHB on the body, thereby potentially causing an unsafe condition.
    Type: Grant
    Filed: April 29, 2013
    Date of Patent: February 10, 2015
    Assignee: Jazz Pharmaceuticals Ireland Limited
    Inventor: Mark Eller
  • Publication number: 20140249222
    Abstract: One embodiment of the present invention is to improve the safety and efficacy of the administration of GHB or a salt thereof to a patient. It has been discovered that the concomitant administration of an MCT inhibitor, such as diclofenac, valproate, or ibuprofen, will affect GHB administration. For example, it has been discovered that diclofenac lowers the effect of GHB in the body, thereby potentially causing an unsafe condition. Furthermore, it has been discovered that valproate increases the effect of GHB on the body, thereby potentially causing an unsafe condition.
    Type: Application
    Filed: April 29, 2013
    Publication date: September 4, 2014
    Applicant: Jazz Pharmaceuticals, Inc.
    Inventor: Mark Eller
  • Patent number: 8772306
    Abstract: One embodiment of the present invention is to improve the safety and efficacy of the administration of GHB or a salt thereof to a patient. It has been discovered that the concomitant administration of an MCT inhibitor, such as diclofenac, valproate, or ibuprofen, will affect GHB administration. For example, it has been discovered that diclofenac lowers the effect of GHB in the body, thereby potentially causing an unsafe condition. Furthermore, it has been discovered that valproate increases the effect of GHB on the body, thereby potentially causing an unsafe condition.
    Type: Grant
    Filed: April 29, 2013
    Date of Patent: July 8, 2014
    Assignee: Jazz Pharmaceuticals, Inc.
    Inventor: Mark Eller
  • Publication number: 20060269924
    Abstract: The use of modulators of Mre 11, tankyrase, the DNA damage pathway and MRN complex formation of the protection of mammals from failure of growth arrest, apoptosis or proliferative senescence.
    Type: Application
    Filed: January 14, 2004
    Publication date: November 30, 2006
    Applicant: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Barbara Gilchrest, Mark Eller
  • Publication number: 20060205782
    Abstract: The present invention relates to a method of providing an antihistaminic effect in a hepatically impaired patient in need thereof comprising administering to said patient an effective antihistaminic amount of a compound of the formula wherein R1 is hydrogen or hydroxy; R2 is hydrogen; or R1 and R2 taken together form a second bond between the carbon atoms bearing R1 and R2; n is an integer of from 1 to 5; R3 is —COOH or —COOalkyl wherein the alkyl moiety has from 1 to 6 carbon atoms and is straight or branched; each of A and B is hydrogen or hydroxy with the proviso that at least one of A or B is hydrogen; or a pharmaceutically acceptable salt and individual isomers thereof.
    Type: Application
    Filed: May 15, 2006
    Publication date: September 14, 2006
    Inventors: James Woodward, Richard Okerholm, Mark Eller, Bruce McNutt
  • Patent number: 7094766
    Abstract: Methods of treatment or prevention of hyperproliferative diseases or pre-cancerous conditions affecting epithelial cells, such as psoriasis, vitiligo, atopic dermatitis, or hyperproliferative or UV-responsive dermatoses, hyperproliferative or allergically mediated diseases of other epithelia and methods for reducing photoaging, or oxidative stress or for prophylaxis against or reduction in the likelihood of the development of skin cancer, are disclosed.
    Type: Grant
    Filed: March 31, 2000
    Date of Patent: August 22, 2006
    Assignee: Trustees of Boston University
    Inventors: Barbara A. Gilchrest, Mina Yaar, Mark Eller
  • Publication number: 20060183704
    Abstract: Described are methods for treating hyperproliferative disorders, including cancers, by administering to the affected mammal (e.g., human) an effective amount of a composition comprising pTT or a composition comprising one or more oligonucleotides which share at least 50% nucleotide sequence identity with the human telomere overhang repeat. Methods of treatment or prevention of hyperproliferative diseases or pre-cancerous conditions affecting epithelial cells, such as psoriasis, atopic dermatitis, or hyperproliferative or UV-responsive dermatoses, hyperproliferative diseases of other epithelia and methods for reducing photoaging, or oxidative stress or for prophylaxis against or reduction in the likelihood of the development of skin cancer, are also disclosed.
    Type: Application
    Filed: April 24, 2006
    Publication date: August 17, 2006
    Inventors: Barbara Gilchrest, Mark Eller, Mina Yaar
  • Publication number: 20060052323
    Abstract: Described are methods for treating hyperproliferative disorders, including cancers, by administering to the affected mammal (e.g., human) an effective amount of a composition comprising one or more oligonucleotides which share at least 33% but less than 100% nucleotide sequence identity with the human telomere overhang repeat. Methods of treatment or prevention of hyperproliferative diseases or pre-cancerous conditions affecting epithelial cells, such as psoriasis, atopic dermatitis, or hyperprolferative diseases of other epithelia and methods for reducing photoaging, or oxidative stress or for prophylaxis against or reduction in the likelihood of the development of skin cancer, are also disclosed. The compositions and methods are also useful to treating other cancers.
    Type: Application
    Filed: August 1, 2005
    Publication date: March 9, 2006
    Inventors: Barbara Gilchrest, Mark Eller
  • Patent number: 6867179
    Abstract: Methods to control, or manipulate, melanocyte and keratinocyte cell death are disclosed. In particular, a method of preventing epidermal melanocyte cell loss due to injury in a vertebrate is disclosed. Also disclosed is a method of inducing hair growth in a vertebrate, a method of inducing hair color in a vertebrate, a method of inducing skin color in a vertebrate, a method of treating baldness in an individual, and a method of treating alopecia areata in an individual.
    Type: Grant
    Filed: August 4, 2000
    Date of Patent: March 15, 2005
    Assignee: Trustees of Boston University
    Inventors: Barbara A. Gilchrest, Mina Yaar, Mark Eller
  • Publication number: 20030175231
    Abstract: Methods to control, or manipulate, melanocyte and keratinocyte cell death are disclosed. In particular, a method of preventing epidermal melanocyte cell loss due to injury in a vertebrate is disclosed. Also disclosed is a method of inducing hair growth in a vertebrate, a method of inducing hair color in a vertebrate, a method of inducing skin color in a vertebrate, a method of treating baldness in an individual, and a method of treating alopecia areata in an individual.
    Type: Application
    Filed: February 4, 1998
    Publication date: September 18, 2003
    Inventors: BARBARA A. GILCHRIST, MINA YAAR, MARK ELLER
  • Patent number: 6147056
    Abstract: Methods of treatment or prevention of hyperproliferative diseases or pre-cancerous conditions affecting epithelial cells, such as psoriasis, vitiligo, atopic dermatitis, or hyperproliferative or UV-responsive dermatoses, hyperproliferative or allergically mediated diseases of other epithelia and methods for reducing photoaging or for prophylaxis against or reduction in the likelihood of the development of skin cancer, are disclosed.
    Type: Grant
    Filed: March 26, 1998
    Date of Patent: November 14, 2000
    Assignee: Trustees of Boston University
    Inventors: Barbara A. Gilchrest, Mina Yaar, Mark Eller